<DOC>
	<DOCNO>NCT02042027</DOCNO>
	<brief_summary>The purpose study test investigational drug Gamunex-C growth blood vessel cornea . This study conduct Dr. Balamurali Ambati Moran Eye Center University Utah . The cornea clear outer front part eye . In corneal neovascularization , blood vessel grow cornea . Corneal neovascularization ocular anterior segment inflammation sight-threatening condition . Lipid deposition edema subsequent scar formation compromise corneal clarity irreversibly . Corneal neovascularization also well recognize risk factor corneal graft failure . In natural state , cornea site immune privilege well suit tissue transplantation . Once vascularized , direct exposure corneal antigens circulate host immune mechanism greatly increase chance rejection [ Collaborative Corneal Transplantation Study ] . Melting inflammation anterior chamber , cornea , ocular surface cause irreversible scar destruction optical element eye , compromise vision . Current standard care condition include use topical steroid sometimes immunosuppressant ( e.g. , cyclosporine ) . These address common underlying corneal neovascularization melt . This Phase 1 clinical trial subconjunctival IVIg ( Gamunex-C ) injection treatment corneal neovascularization set corneal transplantation neovascularization . Candidates corneal transplantation corneal neovascularization one quadrants cross 0.5mm limbus identify inclusion study .</brief_summary>
	<brief_title>Subconjunctival IVIg ( Gamunex-C ) Injection Corneal Neovascularization Inflammatory Conditions</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Corneal Neovascularization</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>1 . Candidates corneal transplantation ( one eye per patient would enrol ) 2 . Patients corneal neovascularization one quadrant cross 1.0 mm limbus time enrollment study 3 . Patients refractory anterior uveitis , nonresponding corneal melt , nonresponding ocular cicatricial pemphigoid 4 . Willing able comply clinic visit studyrelated procedure 5 . Provide sign informed consent 6 . Age 18 1 . Patients receive antiangiogenic antiVEGF medication either systemically intravitreally pathology receive drug within 3 month study enrollment 2 . Patients active corneal infection require additional treatment modality 3 . Patients receive coumadin INR &gt; 2.0 , antithrombotic agent ( e.g. , aspirin , Plavix ) permit discretion investigator 4 . History CVA MI within 6 month prior study enrollment 5 . Uncontrolled BP define SBP &gt; 160 mmHg DBP &gt; 95mmHg patient sit 6 . Pregnant breastfeed woman 7 . Sexually active men* woman childbearing potential** unwilling practice adequate contraception study ( adequate contraceptive measure include stable use oral contraceptive prescription pharmaceutical contraceptive 2 menstrual cycle prior screen ; intrauterine device [ IUD ] ; bilateral tubal ligation ; vasectomy ; condom plus contraceptive sponge , foam , jelly , diaphragm plus contraceptive sponge , foam , jelly ) *Contraception require men document vasectomy . **Postmenopausal woman must amenorrheic least 12 month order consider child bear potential . Pregnancy test contraception require woman document hysterectomy tubal ligation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>corneal neovascularization</keyword>
	<keyword>Gamunex-C</keyword>
	<keyword>IVI-g</keyword>
	<keyword>anterior segment inflammation</keyword>
</DOC>